Identification and Validation of SLC9A2 as A Potential Tumor Suppressor in Colorectal Cancer: Integrating Bioinformatics Analysis with Experimental Confirmation

Abstract

Objective

To uncover the mechanisms underlying the development of colorectal cancer (CRC), we applied bioinformatic analyses to identify key genes and experimentally validated their possible roles in CRC onset and progression.

Methods

We performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis on differentially expressed genes (DEGs), constructed a protein-protein interaction (PPI) network to find the top 10 hub genes, and analyzed their expression in colon adenocarcinoma (COAD) and rectum adenocarcinoma (READ). We also studied the correlation between these genes and immune cell infiltration and prognosis and validated the expression of SLC9A2 in CRC tissues and cell lines using qRT-PCR and Western blotting. Functional experiments were conducted in vitro to investigate the effects of SLC9A2 on tumor growth and metastasis.

Results

We found 130 DEGs, with 45 up-regulated and 85 down-regulated in CRC. GO analysis indicated that these DEGs were primarily enriched in functions related to the regulation of cellular pH, zymogen granules, and transmembrane transporter activity. KEGG pathway analysis revealed that the DEGs played pivotal roles in pancreatic secretion, rheumatoid arthritis, and the IL-17 signaling pathway. We identified 10 hub genes: CXCL1, SLC26A3, CXCL2, MMP7, MMP1, SLC9A2, SLC4A4, CLCA1, CLCA4, and ZG16. GO enrichment analysis showed that these hub genes were predominantly involved in the positive regulation of transcription. Gene expression analysis revealed that CXCL1, CXCL2, MMP1, and MMP7 were highly expressed in CRC, whereas CLCA1, CLCA4, SLC4A4, SLC9A2, SLC26A3, and ZG16 were expressed at lower levels. Survival analysis revealed that 5 key genes were significantly associated with the prognosis of CRC. Both mRNA and protein expression levels of SLC9A2 were markedly reduced in CRC tissues and cell lines. Importantly, SLC9A2 overexpression in SW480 cells led to a notable inhibition of cell proliferation, migration, and invasion. Western blotting analysis revealed that the expression levels of phosphorylated ERK (p-ERK) and phosphorylated JNK (p-JNK) proteins were significantly increased, whereas there were no significant changes in the expression levels of ERK and JNK following SLC9A2 overexpression. Correlation analysis indicated a potential link between SLC9A2 expression and the MAPK signaling pathway.

Conclusion

Our study suggests that SLC9A2 acts as a tumor suppressor through the MAPK pathway and could be a potential target for CRC diagnosis and therapy.

References

[1] BrayF, FerlayJ, SoerjomataramI, et al.. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424

[2] FerlayJ, ShinHR, BrayF, et al.. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 2010, 127(12): 2893-2917

[3] CoppedèF, LopomoA, SpisniR, et al.. Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. World J Gastroenterol, 2014, 20(4): 943-956

[4] SiegelR, DeSantisC, VirgoK, et al.. Cancer treatment and survivorship statistics, 2012. CA Can J Clin, 2012, 62(4): 220-241

[5] GaneshK, StadlerZK, CercekA, et al.. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nature Rev Gastroenterol Hepatol, 2019, 16(6): 361-375

[6] ChenX, HuangY, WangY, et al.. THBS4 predicts poor outcomes and promotes proliferation and metastasis in gastric cancer. J Physiol Biochem, 2019, 75(1): 117-123

[7] BarrettT, WilhiteSE, LedouxP, et al.. NCBI GEO: archive for functional genomics data sets—update. Nucleic Acids Res, 2013, 41: D991-D995 Database issue

[8] YamagishiA, MatsumotoS, WatanabeA, et al.. Gene profiling and bioinformatics analyses reveal time course differential gene expression in surgically resected colorectal tissues. Oncol Rep, 2014, 31(4): 1531-1538

[9] HuY, GaedckeJ, EmonsG, et al.. Colorectal cancer susceptibility loci as predictive markers of rectal cancer prognosis after surgery. Genes Chromosomes Cancer, 2018, 57(3): 140-149

[10] AndersM, FehlkerM, WangQ, et al.. Microarray meta-analysis defines global angiogenesis-related gene expression signatures in human carcinomas. Mol Carcinog, 2013, 52(1): 29-38

[11] WangB, ShiG, ZhuZ, et al.. Sexual difference of small RNA expression in Tetralogy of Fallot. Sci Rep, 2018, 8(1): 12847

[12] Huang daW, ShermanBT, LempickiRA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc, 2009, 4(1): 44-57

[13] Huang daW, ShermanBT, LempickiRA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res, 2009, 37(1): 1-13

[14] ShannonP, MarkielA, OzierO, et al.. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res, 2003, 13(11): 2498-2504

[15] SzklarczykD, GableAL, LyonD, et al.. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res, 2019, 47(D1): D607-D613

[16] BaderGD, HogueCW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinform, 2003, 4: 2

[17] RhodesDR, YuJ, ShankerK, et al.. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia, 2004, 6(1): 1-6

[18] TangZ, LiC, KangB, et al.. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res, 2017, 45(W1): W98-W102

[19] GaoJ, AksoyBA, DogrusozU, et al.. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal, 2013, 6(269): pl1

[20] LiB, SeversonE, PignonJC, et al.. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol, 2016, 17(1): 174

[21] LiT, FanJ, WangB, et al.. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res, 2017, 77(21): e108-e110

[22] UhlénM, FagerbergL, HallströmBM, et al.. Proteomics. Tissue-based map of the human proteome. Science, 2015, 347(6220): 1260419

[23] MoriS, KadochiY, LuoY, et al.. Proton pump inhibitor induced collagen expression in colonocytes is associated with collagenous colitis. World J Gastroenterol, 2017, 23(9): 1586-1593

[24] ZhangD, XiaJ. Somatic synonymous mutations in regulatory elements contribute to the genetic aetiology of melanoma. BMC Med Genomics, 2020, 13(Suppl 5): 43

[25] SunH, OuB, ZhaoS, et al.. USP11 promotes growth and metastasis of colorectal cancer via PPP1CA-mediated activation of ERK/MAPK signaling pathway. EBioMedicine, 2019, 48: 236-247

[26] ArrietaVA, ChenAX, KaneJR, et al.. ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma [published correction appears in Nat Cancer, 2022,3(3):373]. Nat Cancer, 2021, 2(12): 1372-1386

[27] ToorSM, MurshedK, Al-DhaheriM, et al.. Immune Checkpoints in Circulating and Tumor-Infiltrating CD4(+) T Cell Subsets in Colorectal Cancer Patients. Front Immunol, 2019, 10: 2936